摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苄基(2-氧代-5-苯基-2,3-二氢-1H-苯并[E][1,4]二氮杂-3-基)氨基甲酸叔丁酯 | 108895-98-3

中文名称
苄基(2-氧代-5-苯基-2,3-二氢-1H-苯并[E][1,4]二氮杂-3-基)氨基甲酸叔丁酯
中文别名
——
英文名称
benzyl 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamate
英文别名
1,3-dihydro-5-phenyl-3(R,S)-<(benzyloxycarbonyl)-amino>-2H-1,4-benzodiazepin-2-one;(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester;(Z)-benzyl 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamate;1,3-Dihydro-5-phenyl-3(R,S)-[(benzyloxycarbonyl)-amino]-2H-1,4-benzodiazepin-2-one;Benzyl (2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)carbamate;benzyl N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)carbamate
苄基(2-氧代-5-苯基-2,3-二氢-1H-苯并[E][1,4]二氮杂-3-基)氨基甲酸叔丁酯化学式
CAS
108895-98-3
化学式
C23H19N3O3
mdl
——
分子量
385.422
InChiKey
SJZIESNYFPDCPM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    212-213 °C
  • 沸点:
    619.7±55.0 °C(Predicted)
  • 密度:
    1.26±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    79.8
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:47d8dcce9e05ba0f9564c800f1ca8814
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 5-PHENYL-LH-BENZ0 [E] [1, 4] DIAZEPINE COMPOUNDS SUBSTITUTED WITH AN HYDROXAMIC ACID GROUP AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] COMPOSÉS DE 5-PHÉNYL-LH-BENZO [E] [1, 4] DIAZÉPINE SUBSTITUÉS AVEC UN GROUPE D'ACIDE HYDROXAMIQUE EN TANT QU'INHIBITEURS D'HISTONE DÉACÉTYLASE
    申请人:UNIV FIRENZE
    公开号:WO2009081349A1
    公开(公告)日:2009-07-02
    Novel hydroxamate histone deacetylase inhibitors of formula (I) wherein X is C=O or CH2 used as antineoplastic agent.
    新型羟酸组蛋白去乙酰化酶抑制剂化学式(I),其中X为C=O或CH2,用作抗肿瘤药物。
  • [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
    申请人:ENANTA PHARM INC
    公开号:WO2019067864A1
    公开(公告)日:2019-04-04
    The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
    本发明涉及用于治疗呼吸道合胞病毒(RSV)感染的药物剂,该药物剂可以单独或连续给予受试者,治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
  • Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
    申请人:——
    公开号:US20020045747A1
    公开(公告)日:2002-04-18
    Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    公开了抑制β-淀粉样肽释放和/或其合成的化合物,因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物,以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
  • Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
    申请人:Elan Pharmaceuticals, Inc.
    公开号:US06528505B1
    公开(公告)日:2003-03-04
    Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    公开了抑制β-淀粉样肽释放和/或其合成的化合物,因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物,以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
  • [EN] BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS<br/>[FR] DÉRIVÉS BENZODIAZÉPINE UTILISÉS COMME INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV)
    申请人:ENANTA PHARM INC
    公开号:WO2017015449A1
    公开(公告)日:2017-01-26
    The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    本发明公开了化合物的结构式(I),或其药学上可接受的盐、酯或前药:这些化合物抑制呼吸道合胞病毒(RSV)。本发明还涉及包含上述化合物的药物组合物,用于治疗患有RSV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
查看更多